Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
Equities analysts expect Nektar Therapeutics (NASDAQ:NKTR – Get Rating) to post $23.38 million in sales for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for Nektar Therapeutics’ earnings, with the highest sales estimate coming in at $26.60 million and the lowest estimate coming in at $21.29 million. Nektar Therapeutics posted sales of […]
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
Brokerages expect Nektar Therapeutics (NASDAQ:NKTR – Get Rating) to announce sales of $23.38 million for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Nektar Therapeutics’ earnings. The highest sales estimate is $26.60 million and the lowest is $21.29 million. Nektar Therapeutics reported sales of $23.65 million in the same quarter […]
State of New Jersey Common Pension Fund D grew its holdings in Nektar Therapeutics (NASDAQ:NKTR – Get Rating) by 18.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 238,019 shares of the biopharmaceutical company’s stock after buying an additional 36,578 shares during the quarter. State of New Jersey Common Pension Fund D’s […]